Last reviewed · How we verify
Human umbilical cord mesenchymal stem cell injection
Human umbilical cord mesenchymal stem cell injection is a Small molecule drug developed by Shanghai Life Science & Technology. It is currently in Phase 1 development.
At a glance
| Generic name | Human umbilical cord mesenchymal stem cell injection |
|---|---|
| Sponsor | Shanghai Life Science & Technology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Procedural pain
- Arthralgia
- Joint swelling
- Joint stiffness
- Post procedural contusion
- Post procedural haematoma
Key clinical trials
- Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease (PHASE1, PHASE2)
- Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis (PHASE1, PHASE2)
- A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome (PHASE1, PHASE2)
- Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke (PHASE1)
- Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture (PHASE1)
- Extracellular Vesicles for the Treatment of Syringomyelia (PHASE1)
- A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure (PHASE1, PHASE2)
- Clinical Trial Investigating the Effect of Exosomes as a Complementary Treatment in Severe to Moderate Erectile Dysfunction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human umbilical cord mesenchymal stem cell injection CI brief — competitive landscape report
- Human umbilical cord mesenchymal stem cell injection updates RSS · CI watch RSS
- Shanghai Life Science & Technology portfolio CI
Frequently asked questions about Human umbilical cord mesenchymal stem cell injection
What is Human umbilical cord mesenchymal stem cell injection?
Human umbilical cord mesenchymal stem cell injection is a Small molecule drug developed by Shanghai Life Science & Technology.
Who makes Human umbilical cord mesenchymal stem cell injection?
Human umbilical cord mesenchymal stem cell injection is developed by Shanghai Life Science & Technology (see full Shanghai Life Science & Technology pipeline at /company/shanghai-life-science-technology).
What development phase is Human umbilical cord mesenchymal stem cell injection in?
Human umbilical cord mesenchymal stem cell injection is in Phase 1.
What are the side effects of Human umbilical cord mesenchymal stem cell injection?
Common side effects of Human umbilical cord mesenchymal stem cell injection include Procedural pain, Arthralgia, Joint swelling, Joint stiffness, Post procedural contusion, Post procedural haematoma.